• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Immunoglobulin G production in COVID-19 - associations with age, outcome, viral persistence, inflammation and pro-thrombot

tetano

Editor, Senior Moderator
J Infect Public Health


. 2023 Jan 21;16(3):384-392.
doi: 10.1016/j.jiph.2023.01.016. Online ahead of print.
Immunoglobulin G production in COVID-19 - associations with age, outcome, viral persistence, inflammation and pro-thrombotic markers


Anita Pirabe[SUP] 1 [/SUP], Waltraud C Schrottmaier[SUP] 1 [/SUP], Stefan Heber[SUP] 2 [/SUP], Anna Schmuckenschlager[SUP] 1 [/SUP], Sonja Treiber[SUP] 1 [/SUP], David Pereyra[SUP] 3 [/SUP], Jonas Santol[SUP] 3 [/SUP], Erich Pawelka[SUP] 4 [/SUP], Marianna Traugott[SUP] 4 [/SUP], Christian Schörgenhofer[SUP] 5 [/SUP], Tamara Seitz[SUP] 4 [/SUP], Mario Karolyi[SUP] 4 [/SUP], Bernd Jilma[SUP] 5 [/SUP], Ulrike Resch[SUP] 1 [/SUP], Alexander Zoufaly[SUP] 6 [/SUP], Alice Assinger[SUP] 7 [/SUP]



Affiliations

Abstract

Age represents the major risk factor for fatal disease outcome in coronavirus disease (COVID-19) due to age-related changes in immune responses. On the one hand lymphocyte counts continuously decline with advancing age, on the other hand somatic hyper-mutations of B-lymphocytes and levels of class-switched antibodies diminish, resulting in lower neutralizing antibody titers. To date the impact of age on immunoglobulin G (IgG) production in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is unknown. Therefore, we investigated the impact of age on the onset of IgG production and its association with outcome, viral persistence, inflammatory and thrombotic markers in consecutive, hospitalized COVID-19 patients admitted to the Clinic Favoriten (Vienna, Austria) between April and October 2020 that fulfilled predefined inclusion criteria. Three different IgGs against SARS-CoV-2 (spike protein S1, nucleocapsid (NC), and the spike protein receptor binding domain (RBD)) were monitored in plasma of 97 patients upon admission and three times within the first week followed by weekly assessment during their entire hospital stay. We analyzed the association of clinical parameters including C-reactive protein (CRP), D-dimer levels and platelet count as well as viral persistence with the onset and concentration of different anti-SARS-CoV-2 specific IgGs. Our data demonstrate that in older individuals anti-SARS-CoV-2 IgG production increases earlier after symptom onset and that deceased patients have the highest amount of antibodies against SARS-CoV-2 whereas intensive care unit (ICU) survivors have the lowest titers. In addition, anti-SARS-CoV-2 IgG concentrations are not associated with curtailed viral infectivity, inflammatory or thrombotic markers, suggesting that not only serological memory but also other adaptive immune responses are involved in successful viral killing and protection against a severe COVID-19 infection.

Keywords: Age; COVID-19; Immune response; Immunoglobulins; Spike protein.
 
Back
Top Bottom